Pharmacological blockade of CD73 by the selective inhibitor APCP or anti-CD73 monoclonal antibodies (mAb) has the potential to provide numerous anti-tumor effects [19]–[21], both direct and indirect. The gene discussed is NT5E; the disease is neoplasm.